Previous close | 41.08 |
Open | 41.10 |
Bid | 41.01 x 1000 |
Ask | 42.34 x 900 |
Day's range | 41.06 - 41.68 |
52-week range | 34.74 - 47.70 |
Volume | |
Avg. volume | 1,028,503 |
Market cap | 9.22B |
Beta (5Y monthly) | 0.42 |
PE ratio (TTM) | 27.40 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 1.28 (2.94%) |
Ex-dividend date | 30 Jan 2024 |
1y target est | N/A |
Launch of QIAseq xHYB Mycobacterium tuberculosis Panel for research use, enabling culture-free whole genome sequencing from complex samples // Panel significantly accelerates TB outbreak tracking and supports detection and management of antimicrobial resistance, critical needs in TB surveillance and control // Building upon success of leading diagnostics test QuantiFERON-TB Gold Plus as QIAGEN extends portfolio for TB management and control amid globally rising incidence ratesVenlo, the Netherla
Venlo, The Netherlands, April 09, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced plans to release results for the first quarter 2024. Press release date / time: Monday, April 29, shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time. Conference call date / time: Tuesday, April 30, at 15:00 Frankfurt time / 14:00 London time / 09:00 New York time. Three options for joining the conference call Register for call back connection - C
Novel QIAcuity dPCR PanCancer Kits can detect rare mutations of EGFR and BRAF genes at the same time, while saving sample material, reducing time and cost // New QIAseq Targeted RNA-seq Panel for T-cell Receptor allows targeted next-generation sequencing of T-cell receptors, increasing accuracy and sensitivity PAXgene® Urine Liquid Biopsy Set to enable non-invasive sample collection and cell-free DNA stabilization, thereby allowing researchers to make advances in urine liquid biopsyVenlo, the Ne